EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Treatment‐Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T‐Cell Therapy

John B Sanderson iD, Yi-Han Lin, Kimmy Su, Yujie Wang, Andrew Portuguese, Jordan Gauthier, Meredith Durbin, Rahul Banerjee

Movement Disorders Clinical Practice · 2026-06 · 13 (6) · 1539-1543

DOI: 10.1002/mdc3.70452 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 19.11.2025. Verfasst von John B Sanderson und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington Department of Neurology, Seattle, WA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Parkinsonian Disorders, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment‐emergent motor and neurocognitive adverse events (MNTs) are rare but increasingly well‐documented complications of chimeric antigen receptor T‐cell (CAR‐T) therapy. Here, we describe the development of parkinsonism in four patients who received CAR‐T therapy with either B‐cell maturation antigen (BCMA)‐targeting ciltacabtagene autoleucel for multiple myeloma (n = 3) or CD‐19‐targeting axicabtagene autoleucel for lymphoma (n = 1). Cases We report four cases of parkinsonism in patients who received CAR‐T therapy. Two patients had evidence of underlying neurodegenerative parkinsonism, either clinically or through subsequent workup for their movement disorder. All patients received some combination of symptom‐directed and immunomodulatory therapies.

Conclusion

This report describes features of CAR‐T treatment‐emergent parkinsonism, introduces parkinsonism as a potential effect of CD‐19‐targeted CAR‐T therapy, and suggests utility of screening for underlying clinical or biomarker signs of pre‐existing neurodegenerative parkinsonism prior to CAR‐T infusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveParkinsonian DisordersReceptors, Chimeric AntigenAgedHumansMaleMiddle Aged

Stichwörter der Autor:innen

CAR‐T therapyparkinsonismtreatment‐emergent motor and neurocognitive toxicity

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • University of Washington Department of Neurology, Seattle, WA, USA.
  • Department of Neurology, Veteran Affairs Puget Sound Health Care System, Seattle, WA, USA.
  • Division of Hematology and Oncology, University of Washington Department of Internal Medicine, Seattle, WA, USA.
  • Fred Hutchinson Cancer Center, Seattle, WA, USA.

ORCID-Profile: John B Sanderson

Zitieren

APA

Sanderson, J. B., Lin, Y. H., Su, K., Wang, Y., Portuguese, A., Gauthier, J., Durbin, M., & Banerjee, R. (2026). Treatment‐Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T‐Cell Therapy. Movement Disorders Clinical Practice, 13(6), 1539-1543. https://doi.org/10.1002/mdc3.70452

Vancouver

Sanderson JB, Lin YH, Su K, Wang Y, Portuguese A, Gauthier J, et al. Treatment‐Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T‐Cell Therapy. Movement Disorders Clinical Practice. 2026;13(6):1539-1543. doi:10.1002/mdc3.70452

BibTeX
@article{Sanderson2026,
  author = {Sanderson, John B and Lin, Yi-Han and Su, Kimmy and Wang, Yujie and Portuguese, Andrew and Gauthier, Jordan and Durbin, Meredith and Banerjee, Rahul},
  title = {Treatment‐Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T‐Cell Therapy},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1539--1543},
  doi = {10.1002/mdc3.70452}
}
Kostenlos starten →